Biogen Idec Initiates Phase III Clinical Program Of Oral Compound Bg-12 For Multiple Sclerosis
Medical News Today Mon, 15 Jan 2007 0:07 AM PST
Biogen Idec (NASDAQ: BIIB) announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis (MS). [click link for full article]

New antivirals show positive results: Nutra Pharma PharmaBiz Sun, 14 Jan 2007 9:48 PM PST Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and multiple sclerosis has announced that its contract researchers, Eno Research and Development, Inc. (ERDI), recently completed their analysis of a series of microarray studies with ReceptoPharm's antiviral drug candidates in healthy immune cells.

nationalmssociety.org
Milwaukee Journal Sentinel Sun, 14 Jan 2007 4:54 PM PST
The site This is the site of the National Multiple Sclerosis Society, an organization with the stated...

The GM hens whose eggs are designed to save lives
Daily Mail Sun, 14 Jan 2007 4:58 PM PST
Scientists have created a breed of designer chickens with eggs that can produce life-saving drugs. The breakthrough could help the fight against diseases such as cancer and dramatically cut the cost of treatments

Biogen Idec Initiates Phase III Clinical Program of Oral Compound ...
Genetic Engineering News (press release) - New Rochelle,NY,USA
Biogen Idec (NASDAQ: BIIB) announced today that it has initiated the Phase III clinical program of BG-12, an oral fumarate in development for ...

Biogen Idec (BIIB) Initiates Phase III Clinical Program of BG-12
StreetInsider.com (subscription) - Birmingham,MI,USA
Biogen Idec (NASDAQ: BIIB) has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting multiple sclerosis ...